RxDoctor Payments DataLook up a doctor →

Raymond Chow, MD

Cardiology · Gurnee, ILNPI 1356369037

Payments from drug & device makers

$15,463in general payments, 2019–2025

Across 853 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Novartis$1K
  • Pfizer$987
  • Boehringer Ingelheim$918
  • Abbott$830
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$15,29999%
  • Education$1641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,463 in reported general payments places this provider in the 95th percentile of 26 cardiology providers in Illinois.

See all cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,402,417
Medicare patients
1,461
Services billed
9,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban351$403,163
XareltoRivaroxaban208$221,588
EntrestoSacubitril/Valsartan151$198,345
JardianceEmpagliflozin135$130,788
Repatha SureclickEvolocumab45$51,708
FarxigaDapagliflozin Propanediol39$36,581
Dabigatran EtexilateDabigatran Etexilate Mesylate34$13,293
LivaloPitavastatin Calcium15$13,282
NexletolBempedoic Acid11$11,661
Metoprolol Succinate556$9,664
Icosapent Ethyl14$9,291
Atorvastatin Calcium615$6,691
Praluent PenAlirocumab13$6,575
Fenofibrate90$6,427
Ezetimibe163$4,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$987$403,163351 claims
Johnson & JohnsonXarelto$2,740$221,588208 claims
NovartisEntresto$1,385$198,345151 claims
Boehringer IngelheimJardiance$918$130,788135 claims
AstraZenecaFarxiga$632$36,58139 claims
Kowa Pharmaceuticals America, Inc.Livalo$85$13,28215 claims
Esperion Therapeutics, Inc.Nexletol$384$11,66111 claims
Arbor Pharmaceuticals, Inc.Edarbi$95$4,20014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 cardiology providers in Illinois.

Other cardiology in Gurnee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →